Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Gilead Sciences ( NASDAQ: GILD) is scheduled to announce Q4 earnings results on Tuesday, February 11th, after market close. Analysts expect a profit of $1.70 per share (-1.2% Y/Y) on revenue of $7.15B ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences is a steady dividend payer with a growing payout. For a while, though, ...

This story was originally published by Healthbeat. Sign up for their public health newsletters at healthbeat.org/newsletters.

This was the stock's second consecutive day of losses.

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...